# Syneron Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/syneron-bio

- Industry: Biotechnology
- Headquarters: Beijing, China
- Total disclosed funding: $250M
- Latest round: Series B (Mar 31, 2026)
- Investors on record: 15

## About

Based in Beijing, China and founded in 2025, Yuansi Biopeptide (Beijing) Technology Co., Ltd., trading as Syneron Bio, is a biotechnology company dedicated to developing novel macrocyclic peptide drugs. In March 2026, Syneron Bio closed USD 150 million in Series B funding co-led by Decheng Capital, CDH Investments and other investor, Sinovation Ventures, 5Y Capital, GL Ventures, Lenovo Capital and Incubator Group, Abu Dhabi Investment Authority, True Light Capital, Qiming Venture Partners, BioTrack Capital, Lilly Asia Ventures, Biotech Development Fund, and other investors.

The company utilizes its unique Synova™ platform technology to build a rich and differentiated pipeline of macrocyclic peptide drugs, providing breakthrough treatment solutions for global oncology, autoimmune diseases, and rare diseases.

The company generates revenue by developing and providing novel macrocyclic peptide drugs and other related services.

## Funding rounds

- Series B, Mar 31, 2026, $150M — CDH Investments, Abu Dhabi Investment Authority, Qiming Venture Partners, Lilly Asia Ventures, 5Y Capital, Sinovation Ventures, Decheng Capital, Lenovo Capital and Incubator Group, BioTrack Capital, GL Ventures, True Light Capital
- Series A, Dec 11, 2025, $100M — 5Y Capital, Sinovation Ventures, China International Capital Corporation, Lenovo Capital and Incubator Group, Gree Electric Appliances, Inc of Zhuhai, GL Ventures, Astra Zeneca CICC Healthcare Venture Capital Fund, Beijing Xinneng Venture Capital

## Investors

- 5Y Capital (https://capitalatlas.ai/funds/5y-capital) — Series A, Series B
- Sinovation Ventures (https://capitalatlas.ai/funds/sinovation-ventures) — Series A, Series B
- China International Capital Corporation (https://capitalatlas.ai/funds/china-international-capital-corporation) — Series A
- Lenovo Capital and Incubator Group (https://capitalatlas.ai/funds/lenovo-capital-and-incubator-group) — Series A, Series B
- Gree Electric Appliances, Inc of Zhuhai (https://capitalatlas.ai/funds/gree-electric-appliances-inc-of-zhuhai) — Series A
- GL Ventures (https://capitalatlas.ai/funds/gl-ventures) — Series A, Series B
- Astra Zeneca CICC Healthcare Venture Capital Fund — Series A
- Beijing Xinneng Venture Capital (https://capitalatlas.ai/funds/beijing-xinneng-venture-capital) — Series A
- CDH Investments (https://capitalatlas.ai/funds/cdh-investments) — Series B
- Abu Dhabi Investment Authority — Series B
- Qiming Venture Partners (https://capitalatlas.ai/funds/qiming-venture-partners) — Series B
- Lilly Asia Ventures (https://capitalatlas.ai/funds/lilly-asia-ventures) — Series B
- Decheng Capital (https://capitalatlas.ai/funds/decheng-capital) — Series B
- BioTrack Capital (https://capitalatlas.ai/funds/biotrack-capital) — Series B
- True Light Capital (https://capitalatlas.ai/funds/true-light-capital) — Series B